Dean Kendall currently serves as a Principal Scientist at Pfizer, where he specializes in Bioinformatics and Systems Validation within the realm of Business Informatics. His extensive expertise spans several critical areas, including regulatory submission document authoring and quality control, as well as toxicokinetic study management....
Dean Kendall currently serves as a Principal Scientist at Pfizer, where he specializes in Bioinformatics and Systems Validation within the realm of Business Informatics. His extensive expertise spans several critical areas, including regulatory submission document authoring and quality control, as well as toxicokinetic study management. In his current role, Dean is instrumental in ensuring that computerized systems adhere to stringent regulatory standards, facilitating seamless integration within the software development life cycle (SDLC). His commitment to quality management and continuous improvement has positioned him as a key player in advancing Pfizer’s bioinformatics capabilities.
Throughout his career, Dean has successfully led numerous high-impact projects that focus on optimizing research and development (R&D) processes. His prior experience in submissions, toxicokinetics, and reporting has equipped him with a comprehensive understanding of the biopharmaceutical landscape, enabling him to navigate complex regulatory environments with ease. Dean’s proficiency in risk assessment and audit reports ensures that all systems and processes meet Good Laboratory Practice (GLP) standards, thereby safeguarding the integrity of data and enhancing the overall quality of research outputs.
Dean’s collaborative approach fosters strong partnerships across multidisciplinary teams, driving innovation and efficiency in project execution. His passion for leveraging bioinformatics to improve drug development processes not only enhances Pfizer's operational capabilities but also contributes to the advancement of therapeutic solutions that meet patient needs. As a thought leader in his field, Dean continues to explore new methodologies and technologies that can further streamline workflows and enhance the quality of biopharmaceutical research.
